Drugs / XYA02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07670312 | Jul 2026 → Jul 2029 expected | colorectal cancer, gastroesophageal junction adenocarcinoma, non-small cell lung carcinoma, ovarian cancer +1 | XYone Therapeutics, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XYA02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07670312 ↗ |
| Route | Intravenous | “Participants with locally advanced, relapsed, or refractory tumors who will receive an intravenous (IV) infusion of XYA02.” NCT07670312 ↗ |